Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $70.
Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $70.